Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
|ClinicalTrials.gov Identifier: NCT00003156|
Recruitment Status : Terminated
First Posted : April 7, 2004
Last Update Posted : April 11, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent or refractory cancer of the uterus.
|Condition or disease||Intervention/treatment||Phase|
|Sarcoma||Drug: topotecan hydrochloride||Phase 2|
OBJECTIVES: I. Estimate the antitumor activity of topotecan in patients with recurrent or refractory carcinosarcoma of the uterus who have failed standard therapy. II. Determine the nature and degree of toxic effects of topotecan in these patients.
OUTLINE: Patients receive topotecan IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for a minimum of 1 course in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease continue treatment for at least three courses. Patients are followed every 4 months for 2 years, every 6 months for 3 years, and then periodically thereafter until death.
PROJECTED ACCRUAL: Approximately 25-40 patients will be accrued for this study within 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus|
|Study Start Date :||June 1998|
|Primary Completion Date :||October 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003156
Show 46 Study Locations
|Study Chair:||David S. Miller, MD||Simmons Cancer Center|